Abstract DNA-Damage Response (DDR) proteins are crucial for maintaining the integrity of the genome by identifying and repairing errors in DNA. Variants affecting their function can have severe consequences since failure to repair damaged DNA can result in cells turning cancerous. Here, we compare germline and somatic variants in DDR genes, specifically looking at their locations in the corresponding three-dimensional (3D) structures, Pfam domains, and protein–protein interaction interfaces. We show that somatic variants in metastatic cases are more likely to be found in Pfam domains and protein interaction interfaces than are pathogenic germline variants or variants of unknown significance (VUS). We also show that there are hotspots in the...
Trabajo presentado en el XII Symposium on Bioinformatics (XII Jornadas de Bioinformática), celebrado...
Technological advances in DNA sequencing techniques provide new resources and opportunities to study...
Pathogenic mutations in BRCA1 are associated with an increased risk of hereditary breast, ovarian, a...
The BRCA1/2 germline and/or somatic pathogenic variants (PVs) are key players in the hereditary pred...
The BRCA1/2 germline and/or somatic pathogenic variants (PVs) are key players in the hereditary pred...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
Abstract Background Discriminating driver mutations from the ones that play no role in cancer is a s...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
Trabajo presentado en el XII Symposium on Bioinformatics (XII Jornadas de Bioinformática), celebrado...
Technological advances in DNA sequencing techniques provide new resources and opportunities to study...
Pathogenic mutations in BRCA1 are associated with an increased risk of hereditary breast, ovarian, a...
The BRCA1/2 germline and/or somatic pathogenic variants (PVs) are key players in the hereditary pred...
The BRCA1/2 germline and/or somatic pathogenic variants (PVs) are key players in the hereditary pred...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
Abstract Background Discriminating driver mutations from the ones that play no role in cancer is a s...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic response. We sys...
Trabajo presentado en el XII Symposium on Bioinformatics (XII Jornadas de Bioinformática), celebrado...
Technological advances in DNA sequencing techniques provide new resources and opportunities to study...
Pathogenic mutations in BRCA1 are associated with an increased risk of hereditary breast, ovarian, a...